使用瑞德西韦治疗重症肌无力和 COVID-19。
Use of Remdesivir in Myasthenia gravis and COVID-19.
机构信息
Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
Division of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Pharmacotherapy. 2021 Jun;41(6):546-550. doi: 10.1002/phar.2524. Epub 2021 Apr 27.
Abstract
Myasthenia gravis and the associated pharmacologic management options could place patients at higher risk of contracting severe acute respiratory syndrome coronavirus 2 and exhibiting more severe manifestations of the novel coronavirus disease 2019 (COVID-19). Multiple agents have been studied for the management of the COVID-19, including remdesivir. To date, no published reports have evaluated the utilization of the antiviral remdesivir in patients with myasthenia gravis. We describe the first reported clinical course of three patients with myasthenia gravis who safely received remdesivir in combination with dexamethasone for the management of COVID-19.
摘要
重症肌无力和相关的药物治疗选择可能使患者面临更高的感染严重急性呼吸综合征冠状病毒 2 的风险，并表现出更严重的新型冠状病毒病 2019（COVID-19）症状。已经有多种药物被研究用于 COVID-19 的治疗，包括瑞德西韦。迄今为止，尚未有研究评估在重症肌无力患者中使用抗病毒药物瑞德西韦的情况。我们描述了首例接受瑞德西韦联合地塞米松治疗 COVID-19 的三位重症肌无力患者的临床经过。
相似文献
1
Use of Remdesivir in Myasthenia gravis and COVID-19.
Pharmacotherapy. 2021 Jun;41(6):546-550. doi: 10.1002/phar.2524. Epub 2021 Apr 27.
2
A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone.
Medicine (Baltimore). 2021 May 7;100(18):e25701. doi: 10.1097/MD.0000000000025701.
3
Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
PLoS One. 2022 Feb 17;17(2):e0262564. doi: 10.1371/journal.pone.0262564. eCollection 2022.
4
Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
Ann Intern Med. 2021 Oct;174(10):1395-1403. doi: 10.7326/M21-0857. Epub 2021 Aug 17.
5
Real-life use of remdesivir in hospitalized patients with COVID-19.
Rev Esp Quimioter. 2021 Apr;34(2):136-140. doi: 10.37201/req/018.2021. Epub 2021 Mar 6.
6
Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
J Am Osteopath Assoc. 2020 Dec 1;120(12):926-933. doi: 10.7556/jaoa.2020.156.
7
Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement.
J Med Virol. 2021 Sep;93(9):5367-5375. doi: 10.1002/jmv.27049. Epub 2021 May 31.
8
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.
Infection. 2021 Jun;49(3):401-410. doi: 10.1007/s15010-020-01557-7. Epub 2021 Jan 2.
9
Rapid review for the anti-coronavirus effect of remdesivir.
Drug Discov Ther. 2020;14(2):73-76. doi: 10.5582/ddt.2020.01015.
10
USA stockpiling of remdesivir: How should the world respond?
J Comp Eff Res. 2020 Dec;9(18):1243-1246. doi: 10.2217/cer-2020-0174. Epub 2020 Dec 4.
引用本文的文献
1
Remdesivir: treatment of COVID-19 in special populations.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3829-3855. doi: 10.1007/s00210-023-02927-2. Epub 2024 Jan 5.
2
The relationship between myasthenia gravis and COVID-19: a systematic review.
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):83. doi: 10.1186/s41983-022-00516-3. Epub 2022 Jul 7.
3
Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review.
Clin Neurol Neurosurg. 2022 Feb;213:107140. doi: 10.1016/j.clineuro.2022.107140. Epub 2022 Jan 22.
4
Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID-19.
Muscle Nerve. 2022 Apr;65(4):447-452. doi: 10.1002/mus.27497. Epub 2022 Feb 9.
本文引用的文献
1
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update.
Crit Care Med. 2021 Mar 1;49(3):e219-e234. doi: 10.1097/CCM.0000000000004899.
2
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
3
Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report.
Clin Pract Cases Emerg Med. 2020 Nov;4(4):524-526. doi: 10.5811/cpcem.2020.9.49049.
4
Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes.
Front Neurol. 2020 Sep 11;11:1053. doi: 10.3389/fneur.2020.01053. eCollection 2020.
5
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
6
Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.
J Clin Neuromuscul Dis. 2020 Sep;22(1):60-62. doi: 10.1097/CND.0000000000000316.
7
Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection.
Neurology. 2020 Nov 3;95(18):840-843. doi: 10.1212/WNL.0000000000010651. Epub 2020 Aug 14.
8
Description of 3 patients with myasthenia gravis and COVID-19.
J Neurol Sci. 2020 Oct 15;417:117053. doi: 10.1016/j.jns.2020.117053. Epub 2020 Jul 22.
9
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
10
COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.
Clin Neurol Neurosurg. 2020 Sep;196:106045. doi: 10.1016/j.clineuro.2020.106045. Epub 2020 Jun 25.
Zotero 插件